Search Results - "Juric, Dejan"

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer by André, Fabrice, Ciruelos, Eva, Rubovszky, Gabor, Campone, Mario, Loibl, Sibylle, Rugo, Hope S, Iwata, Hiroji, Conte, Pierfranco, Mayer, Ingrid A, Kaufman, Bella, Yamashita, Toshinari, Lu, Yen-Shen, Inoue, Kenichi, Takahashi, Masato, Pápai, Zsuzsanna, Longin, Anne-Sophie, Mills, David, Wilke, Celine, Hirawat, Samit, Juric, Dejan

“…PIK3CA mutations occur in approximately 40% of patients with hormone receptor–positive breast cancer. A PI3K inhibitor, alpelisib, combined with fulvestrant…”
Get full text

Cell Atlas of The Human Fovea and Peripheral Retina by Yan, Wenjun, Peng, Yi-Rong, van Zyl, Tavé, Regev, Aviv, Shekhar, Karthik, Juric, Dejan, Sanes, Joshua R.

“…Most irreversible blindness results from retinal disease. To advance our understanding of the etiology of blinding diseases, we used single-cell RNA-sequencing…”
Get full text

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study by Rugo, Hope S, Lerebours, Florence, Ciruelos, Eva, Drullinsky, Pamela, Ruiz-Borrego, Manuel, Neven, Patrick, Park, Yeon Hee, Prat, Aleix, Bachelot, Thomas, Juric, Dejan, Turner, Nicholas, Sophos, Nickolas, Zarate, Juan Pablo, Arce, Christina, Shen, Yu-Ming, Turner, Stuart, Kanakamedala, Hemanth, Hsu, Wei-Chun, Chia, Stephen

“…Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced…”
Get full text

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer by Mayer, Ingrid A, Abramson, Vandana G, Formisano, Luigi, Balko, Justin M, Estrada, Mónica V, Sanders, Melinda E, Juric, Dejan, Solit, David, Berger, Michael F, Won, Helen H, Li, Yisheng, Cantley, Lewis C, Winer, Eric, Arteaga, Carlos L

“…Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110α, has shown synergistic antitumor activity with endocrine therapy against ER…”
Get full text

Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer by Pereira, Bernard, Chen, Christopher T., Goyal, Lipika, Walmsley, Charlotte, Pinto, Christopher J., Baiev, Islam, Allen, Read, Henderson, Laura, Saha, Supriya, Reyes, Stephanie, Taylor, Martin S., Fitzgerald, Donna M., Broudo, Maida Williams, Sahu, Avinash, Gao, Xin, Winckler, Wendy, Brannon, A. Rose, Engelman, Jeffrey A., Leary, Rebecca, Stone, James R., Campbell, Catarina D., Juric, Dejan

“…In patients with metastatic cancer, spatial heterogeneity of somatic alterations may lead to incomplete assessment of a cancer’s mutational profile when…”
Get full text

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis by Brastianos, Priscilla K., Strickland, Matthew R., Lee, Eudocia Quant, Wang, Nancy, Cohen, Justine V., Chukwueke, Ugonma, Forst, Deborah Anne, Eichler, April, Overmoyer, Beth, Lin, Nancy U., Chen, Wendy Y., Bardia, Aditya, Juric, Dejan, Dagogo-Jack, Ibiayi, White, Michael D., Dietrich, Jorg, Nayyar, Naema, Kim, Albert E., Alvarez-Breckenridge, Christopher, Mahar, Maura, Mora, Joana L., Nahed, Brian V., Jones, Pamela S., Shih, Helen A., Gerstner, Elizabeth R., Giobbie-Hurder, Anita, Carter, Scott L., Oh, Kevin, Cahill, Daniel P., Sullivan, Ryan J.

“…Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single…”
Get full text

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors by Vora, Sadhna R., Juric, Dejan, Kim, Nayoon, Mino-Kenudson, Mari, Huynh, Tiffany, Costa, Carlotta, Lockerman, Elizabeth L., Pollack, Sarah F., Liu, Manway, Li, Xiaoyan, Lehar, Joseph, Wiesmann, Marion, Wartmann, Markus, Chen, Yan, Cao, Z. Alexander, Pinzon-Ortiz, Maria, Kim, Sunkyu, Schlegel, Robert, Huang, Alan, Engelman, Jeffrey A.

“…Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have…”
Get full text

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors by Juric, Dejan, Baselga, José

Get full text

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer by Coates, James T, Sun, Sheng, Leshchiner, Ignaty, Thimmiah, Nayana, Martin, Elizabeth E, McLoughlin, Daniel, Danysh, Brian P, Slowik, Kara, Jacobs, Raquel A, Rhrissorrakrai, Kahn, Utro, Filippo, Levovitz, Chaya, Denault, Elyssa, Walmsley, Charlotte S, Kambadakone, Avinash, Stone, James R, Isakoff, Steven J, Parida, Laxmi, Juric, Dejan, Getz, Gad, Bardia, Aditya, Ellisen, Leif W

“…Sacituzumab govitecan (SG), the first antibody-drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7…”
Get more information

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer by Johnson, Shawn F., Cruz, Cristina, Greifenberg, Ann Katrin, Dust, Sofia, Stover, Daniel G., Chi, David, Primack, Benjamin, Cao, Shiliang, Bernhardy, Andrea J., Coulson, Rhiannon, Lazaro, Jean-Bernard, Kochupurakkal, Bose, Sun, Heather, Unitt, Christine, Moreau, Lisa A., Sarosiek, Kristopher A., Scaltriti, Maurizio, Juric, Dejan, Baselga, José, Richardson, Andrea L., Rodig, Scott J., D’Andrea, Alan D., Balmaña, Judith, Johnson, Neil, Geyer, Matthias, Serra, Violeta, Lim, Elgene, Shapiro, Geoffrey I.

“…Although poly(ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired…”
Get full text

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 by Ebi, Hiromichi, Costa, Carlotta, Faber, Anthony C., Nishtala, Madhuri, Kotani, Hiroshi, Juric, Dejan, Pelle, Patricia Della, Song, Youngchul, Yano, Seiji, Mino-Kenudson, Mari, Benes, Cyril H., Engelman, Jeffrey A.

“…The PI3K pathway is genetically altered in excess of 70% of breast cancers, largely through PIK3CA mutation and HER2 amplification. Preclinical studies have…”
Get full text

Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers by Klotz, Remi, Thomas, Amal, Teng, Teng, Han, Sung Min, Iriondo, Oihana, Li, Lin, Restrepo-Vassalli, Sara, Wang, Alan, Izadian, Negeen, MacKay, Matthew, Moon, Byoung-San, Liu, Kevin J, Ganesan, Sathish Kumar, Lee, Grace, Kang, Diane S, Walmsley, Charlotte S, Pinto, Christopher, Press, Michael F, Lu, Wange, Lu, Janice, Juric, Dejan, Bardia, Aditya, Hicks, James, Salhia, Bodour, Attenello, Frank, Smith, Andrew D, Yu, Min

“…Hematogenous metastasis is initiated by a subset of circulating tumor cells (CTC) shed from primary or metastatic tumors into the blood circulation. Thus, CTCs…”
Get more information

Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates by Ullal, Adeeti V, Peterson, Vanessa, Agasti, Sarit S, Tuang, Suan, Juric, Dejan, Castro, Cesar M, Weissleder, Ralph

“…Immunohistochemistry-based clinical diagnoses require invasive core biopsies and use a limited number of protein stains to identify and classify cancers. We…”
Get more information

Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens by Giedt, Randy J., Pathania, Divya, Carlson, Jonathan C. T., McFarland, Philip J., del Castillo, Andres Fernandez, Juric, Dejan, Weissleder, Ralph

“…Serial tissue sampling has become essential in guiding modern targeted and personalized cancer treatments. An alternative to image guided core biopsies are…”
Get full text

FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma by Zhen, Yuanli, Liu, Kai, Shi, Lei, Shah, Simran, Xu, Qin, Ellis, Haley, Balasooriya, Eranga R., Kreuzer, Johannes, Morris, Robert, Baldwin, Albert S., Juric, Dejan, Haas, Wilhelm, Bardeesy, Nabeel

“…Genomic alterations that activate Fibroblast Growth Factor Receptor 2 (FGFR2) are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to…”
Get full text

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies by Juric, Dejan, de Bono, Johann S, LoRusso, Patricia M, Nemunaitis, John, Heath, Elisabeth I, Kwak, Eunice L, Macarulla Mercadé, Teresa, Geuna, Elena, Jose de Miguel-Luken, Maria, Patel, Chirag, Kuida, Keisuke, Sankoh, Serap, Westin, Eric H, Zohren, Fabian, Shou, Yaping, Tabernero, Josep

“…To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational…”
Get full text

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma by Wu, Qibiao, Zhen, Yuanli, Shi, Lei, Vu, Phuong, Greninger, Patricia, Adil, Ramzi, Merritt, Joshua, Egan, Regina, Wu, Meng-Ju, Yin, Xunqin, Ferrone, Cristina R, Deshpande, Vikram, Baiev, Islam, Pinto, Christopher J, McLoughlin, Daniel E, Walmsley, Charlotte S, Stone, James R, Gordan, John D, Zhu, Andrew X, Juric, Dejan, Goyal, Lipika, Benes, Cyril H, Bardeesy, Nabeel

“…FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring FGFR2 fusions. However, the response rate is moderate, and resistance…”
Get more information

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer by Rodón, Jordi, Demanse, David, Rugo, Hope S, Burris, Howard A, Simó, Rafael, Farooki, Azeez, Wellons, Melissa F, André, Fabrice, Hu, Huilin, Vuina, Dragica, Quadt, Cornelia, Juric, Dejan

“…Hyperglycemia is an on-target effect of PI3Kα inhibitors. Early identification and intervention of treatment-induced hyperglycemia is important for improving…”
Get full text

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer by Tao, Jessica J, Castel, Pau, Radosevic-Robin, Nina, Elkabets, Moshe, Auricchio, Neil, Aceto, Nicola, Weitsman, Gregory, Barber, Paul, Vojnovic, Borivoj, Ellis, Haley, Morse, Natasha, Viola-Villegas, Nerissa Therese, Bosch, Ana, Juric, Dejan, Hazra, Saswati, Singh, Sharat, Kim, Phillip, Bergamaschi, Anna, Maheswaran, Shyamala, Ng, Tony, Penault-Llorca, Frédérique, Lewis, Jason S, Carey, Lisa A, Perou, Charles M, Baselga, José, Scaltriti, Maurizio

“…Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common and…”
Get more information

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR by Cleary, James M., Calvo, Emiliano, Moreno, Victor, Juric, Dejan, Shapiro, Geoffrey I., Vanderwal, Carol Ann, Hu, Beibei, Gifford, Maryella, Barch, David, Roberts-Rapp, Lisa, Ansell, Peter J., Xiong, Hao, Ocampo, Christopher, Tolcher, Anthony W.

“…Summary Losatuxizumab vedotin (formerly ABBV-221) is a second-generation antibody-drug conjugate targeting epidermal growth factor receptor (EGFR). In this…”
Get full text